Benefits of Long-Term Routine Lab Drug Toxicity Monitoring Unclear in RA

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 26, 2025.

via HealthDay

TUESDAY, Aug. 26, 2025 -- For patients with rheumatoid arthritis (RA) using disease-modifying antirheumatic drugs (DMARDs), long-term routine laboratory toxicity monitoring (lt-RLTM) indicates that most very abnormal laboratory results are already known or suspected, according to a study published online Aug. 26 in the Annals of Internal Medicine.

Evy Ulijn, M.D., from Sint Maartenskliniek in Nijmegen, Netherlands, and colleagues examined the cumulative incidence of abnormal and very abnormal laboratory monitoring results among patients with RA after at least six months of DMARD use in a retrospective cohort study conducted in the Netherlands from July 2008 to April 2020. The probabilities of abnormal results were calculated for alanine aminotransferase, the estimated glomerular filtration rate (eGFR), hemoglobin, leukocyte count, and platelet count.

The analyses included 4,774 patients with RA who underwent 59,555 lt-RLTM test sets over 18,383 patient-years. The researchers found that for the five tests, the cumulative probabilities of very abnormal laboratory results varied from 0.2 percent for leukocyte count to 6.6 percent for eGFR at two years and from 0.3 to 11 percent, respectively, at five years. The 449 new very abnormal results mainly occurred after a dose increase (6.5 percent), were often already known or suspected (47.7 percent), were thought to be unrelated to DMARD use (24.1 percent), or did not lead to action (35.8 percent). For less serious abnormal results, the incidence was higher, reaching 39 percent for eGFR <60 mL/min/1.73 m2 and 61 percent for hemoglobin levels below 7.5 mmol/L or below 8 mmol/L for women and men, respectively.

"The long-standing practice of performing frequent lt-RLTM in all patients with RA using DMARDs should be reconsidered, as our findings call into question the value of nontargeted monitoring," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-08-27 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords